BLS Pharmaceuticals Limited

As of June 30, 2026, BLS Pharmaceuticals Limited carries a market capitalization of 213.88M, placing it among publicly traded companies globally. Its enterprise value stands at 209.02M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, BLS Pharmaceuticals Limited has 229.98M shares outstanding.

As of June 30, 2026, BLS Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 13.40. The price-to-sales ratio is 2.78, and the price-to-book ratio stands at 6.88.

As of June 30, 2026, BLS Pharmaceuticals Limited trades at an EV/EBITDA multiple of 12.16 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.82 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.23 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 209.02M versus a market cap of 213.88M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BLS Pharmaceuticals Limited maintains a current ratio of 2.90, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.13, indicating elevated leverage, while an interest coverage ratio of 37.37 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BLS Pharmaceuticals Limited recorded an income tax benefit of -239,522.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 15.16M, leaving 15.40M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, BLS Pharmaceuticals Limited's stock has gained approximately 143.42% over the past 52 weeks. The 50-day moving average sits at 1.05, while the 200-day moving average is 0.78.

Over the twelve months ended June 30, 2026, BLS Pharmaceuticals Limited generated 74.16M in revenue and converted that into 15.40M in net income, yielding earnings per share of 0.07. EBITDA reached 17.19M, while operating income came in at 15.80M.

As of June 30, 2026, BLS Pharmaceuticals Limited holds 13.29M in cash and equivalents against 8.43M in total debt, resulting in a net debt position of -10.26M. Total book value stands at 31.09M, with working capital of 26.99M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, BLS Pharmaceuticals Limited posted a gross margin of 56.04, reflecting its pricing power and cost economics. The operating margin of 21.31 and net profit margin of 20.76 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -1.76, meaning BLS Pharmaceuticals Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

BLS Pharmaceuticals Limited's most recent stock split took place on June 24, 2026 with a 10:1 split ratio.

As of June 30, 2026, BLS Pharmaceuticals Limited has an Altman Z-Score of 9.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.